Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

VivoSim Labs, Inc. Common Stock

VIVS

VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The Company provides liver and intestinal toxicology insights using its new approach methodologies and models and offers liver toxicology predictive screening and research services, as well as services to predict and study the intestinal side effect profiles of therapeutic candidates at all stages of drug development. Its 3D human tissue platform includes expertise in 3D organoids, such as spheroids, and proprietary cell culture techniques.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $0.118 – $0.129
Volume 214,414
Market cap $3M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$2.43M
Price / earnings
—
Price / book
0.34×
Price / sales
18.03×
EV / sales
-45.41×
EV / EBITDA
0.52×

Profitability

Earnings per share
-$0.51
Return on assets
-103.47%
Return on equity
-141.78%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
3.5×
Quick ratio
3.49×
Cash ratio
3.19×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$10.29M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for VIVS, quarterly periods
Line itemQ2 FY2027 Sep 30, 2026Q1 FY2027 Jun 30, 2026Q4 FY2026 Mar 31, 2026Q3 FY2026 Dec 31, 2025Q2 FY2026 Sep 30, 2025Q1 FY2026 Jun 30, 2025
Revenue$51K$18K$40K$26K$28K$37K
Cost of revenue$56K$0$0$0$0$0
Gross profit-$5K$18K$40K$26K$28K$37K
Selling, general and administrative$2.22M$1.65M$2.1M$1.64M$1.74M$1.95M
Research and development$1.1M$1.13M$1.13M$1.14M$923K$1M
Total operating expenses$3.31M$2.78M$3.23M$2.78M$2.66M$2.95M
Operating income-$3.32M-$2.76M-$3.19M-$2.75M-$2.64M-$2.92M
Interest expense$0-$4K-$4K-$4K$0-$4K
Income before taxes-$475K-$1.34M-$5.76M-$2.69M-$2.54M-$2.84M
Income taxes$0$3K$0$0$2K$0
Net income-$475K-$1.34M-$5.76M-$2.69M-$2.55M-$2.84M
Net income attributable to common shareholders-$475K-$1.34M-$5.76M-$2.69M-$2.55M-$2.84M
EBITDA-$3.28M-$2.72M-$3.14M-$2.7M-$2.58M-$2.85M
Basic earnings per share-$0.03-$0.25-$2.19-$1.03-$0.98-$1.14
Diluted earnings per share-$0.03-$0.25-$2.19-$1.03-$0.98-$1.14

Recent news

Company coverage with links to the original publishers.

Publication times in UTC

No recent company news found.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.